{"preliminary_commentary":{"by_channel":{"x_thread":10,"podcast":7,"youtube":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07475806\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT07475806","nct_id":"NCT07475806","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07475806. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive enfortumab vedotin on days 1 and 8 of every 21-day cycle and pembrolizumab on day 1 of every 21-day cycle.","label":"Enfortumab Vedotin with Pembrolizumab","type":"EXPERIMENTAL"}],"collaborators":["Pfizer"],"completion_date":{"date":"2031-04-30","type":"ESTIMATED"},"conditions":["Muscle-invasive Bladder Cancer"],"enrollment":{"count":240,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Enfortumab Vedotin","otherNames":["ASG-22CE","PADCEV"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-20","lead_sponsor":"Astellas Pharma Global Development, Inc.","official_title":"An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in Participants With Muscle-invasive Bladder Cancer (EV-209)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-11-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall clinical complete response (cCR) rate after treatment with enfortumab vedotin in combination with pembrolizumab as assessed by investigator","timeFrame":"Up to 27 weeks"},{"measure":"Bladder-intact event-free survival (BI-EFS) rate in participants who achieve cRC after 9 cycles of treatment with enfortumab vedotin in combination with pembrolizumab as assessed by investigator","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2026-03-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","url":"https://clinicaltrials.gov/study/NCT07475806"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07475806"}